CROP to Infuse its ‘CannaDrink’ Functional Beverage With Naturally Splendid’s HempOmega™
Momentum Public Relations
Press Release: October 3, 2018
CROP Infrastructure Corp. (CSE: CROP) (CSE: CROP.CN) (OTC: CRXPF)(Frankfurt: 2FR) (“CROP“ or the “Company“) announces that further to its LOI with Naturally Splendid Enterprises (TSX-V: NSP)(OTCQB: NSPDF) (previously announced on August 14th 2018) CROP will utilize NSP’s proprietary HempOmega™ powder created from microencapsulated hemp seed oil in its ‘CannaDrink’ functional beverage line currently being developed.
CannaDrink will now be available in all other jurisdictions containing HempOmega™ where CBD products are not yet approved. CROP’s new cannabis-infused line of soft drinks called CannaDrink will be a zero calorie, non-GMO, ketogenic-friendly line of soda pop, tea, and coffee variations.
HempOmega™ is a unique and proprietary homogenous powder created from microencapsulated hemp seed oil. It is a high-quality and sustainable omega fatty acid alternative ingredient. Due to its unique powder format, it solves the formulation challenge manufacturers face when trying to add oil to existing products and has proven to increase the bioavailability of omega fatty acids. The global carbonated soft drinks market is projected to reach USD 605.6 billion by 2025, according to a March 2018 report by Grand View Research, Inc.
In addition to its CannaDrink beverage line, CROP is working with Naturally Splendid to develop a “Hempire” branded hulled hemp seed and protein powder product line. CROP and Naturally Splendid are currently testing a variety of flavors and formulations created by NSP specifically for the Hempire Brand that will be enhanced with NSP’s HempOmega™.
Naturally Splendid CEO Mr. Douglas Mason states, “We are pleased to be working with CROP to create quality, white-labelled hemp products for the Hempire brand as well as providing our proprietary HempOmega™ ingredient for CROP’s innovative CannaDrink functional soft drink line. CannaDrink is formulated to deliver superior omega nutrition, by utilizing Naturally Splendid’s proprietary HempOmega™it provides ‘first mover advantage’ for Naturally Splendid and CROP to formulate cannabis formulated beverages and edibles as HempOmega™ has been approved for product fortification without the concern or restrictions of cannabinoid formulated beverages and edibles
Michael Yorke, CEO and Director of CROP Infrastructure states: “We believe in the nutritional spectrum and health benefits of both hemp and CBD so adding a consumer goods vertical was a logical progression as consumer data shows strong trends in plant-based foods and nutritional products. We see it as a tremendous opportunity for CROP Infrastructure’s branding & IP portfolio.”
About CROP
Crop has a portfolio of cannabis projects including cultivation properties in California, two in Washington State, two in Nevada consisting of 2,800 acres including extraction, 3 dispensary applications, with international focuses in Jamaica and Italy. CROP has developed a portfolio of assets including Canna Drink with US and Italian distribution rights to over 55 topical products and a portfolio of 16 Cannabis brands.
Disclaimer for Forward-Looking Information
Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. In addition, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970. Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding CannaDrink; the technological effects of CannaDrink; the intention to expand its portfolio; and execute on its business plan. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding the regulatory and legal framework regarding the cannabis industry in general among all levels of government and zoning; risks associated with applicable securities laws and stock exchange rules relating to the cannabis industry; risks associated with maintaining its interests in its various assets; the ability of the Company to finance operations and execute its business plan and other factors beyond the control of the Company. Such forward-looking statements should therefore be construed in light of such factors, and the Company is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
The CSE has not reviewed, approved or disapproved the content of this press release.
Company Contact
Michael Yorke – CEO & Director
E-mail: info@cropcorp.com
Website: http://www.cropcorp.com
Phone: +1-604-484-4206
- Published in Business, CROP Infrastructure, Medical Marijuana, News Home
Tetra Bio-Pharma Moves PPP001 Closer to Commercial Manufacturing with the Issuance of a Drug Establishment License to Ford’s Pharmacy
Momentum Public Relations
Press Release: October 3, 2018
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), in partnership with Ford’s Family Pharmacy and Wellness Center, have developed and implemented a pharmaceutical quality system for Canada’s first botanical-based prescription drug PPP001. The Good Manufacturing Practices, Regulatory Operations and Regions Branch, Health Canada completed the inspection of Ford’s manufacturing facility. A Drug Establishment License (DEL) was granted after having inspected and assessed the facility as being in compliance with the requirements of Divisions 2 to 4 of the Food and Drug Regulations thereby allowing Ford’s to conduct the fabrication, packaging and labeling of PPP001.
Dr. Guy Chamberland, M.Sc., Ph.D., Interim CEO and CSO of Tetra Bio-Pharma stated, “This is a significant accomplishment for Tetra and Ford’s. The manufacturing of a botanical drug is a complex operation and we have demonstrated to Health Canada that we are able to manufacture PPP001 in compliance with the requirements for a prescription drug. The DEL was required not just to manufacture the commercial lots but simply to enable Tetra to apply for approval and obtain the Drug Identification Number (DIN). Tetra is now in an excellent position to focus its activities on scale-up to ensure that we can supply the market demand for a first cannabis botanical drug. The DEL, a recognition of the pharmaceutical GMP quality process by Health Canada, was a critical milestone for Tetra to achieve thereby allowing the corporation to accelerate its plans to register cannabis drugs around the world including Europe and the USA.”
Dr. Peter Ford, CEO of Ford’s Family Pharmacy and Wellness Centre stated, “This has been a true team effort between Tetra and Ford’s and will potentially represent the very first smokable dosage form in Canada and beyond. We are both very much committed to the DIN application.”
Ofer Yifrach-Stav, Tetra Bio-Pharma Vice President, Pharmaceutical Compliance and Quality, said, “Tetra is proud to present a significant milestone in the development of PPP001, a prescription drug that contains a botanical ingredient, manufactured under the stringent requirements and regulations of Health Canada. The GMP inspection addressed a wide range of production activities, and the results demonstrate our consistent adherence to establish procedures at every step of the production process, as well as our ability to provide a high-quality, clean, safe and reliable product. We are excited to take the next steps in the development of cannabis botanical drugs with the potential of making them widely available to the public.”
About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
About Ford’s Family Pharmacy and Wellness Centre
Since 1997, Ford’s Family Pharmacy & Wellness Centre has helped clients improve and prolong their health, wellness and vitality by providing personalized compounding and wellness solutions. Our team, which currently consists of four pharmacists: Peter Ford, Bryan Sinclair, Candy Aguinaga, and Taylor White, 14 pharmacy technicians/assistants and two registered nurses, is attentive, compassionate, courteous and responsive. We pride ourselves on providing innovative solutions to complex medical problems, and work with Canadian healthcare providers (including physicians, veterinarians and dentists) to create well-rounded, comprehensive natural and compounding treatment plans. Our consultative approach, state-of-the-art technology and unique “Functional Medicine” position means we will work with you one-on-one to understand the root cause of your pain or other health issues and apply all our resources to developing the treatment that is right for you.
For more information visit: www.fordrx.com
Source: Tetra Bio-Pharma
- Published in Business, Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
Hillcrest to Commence Operations to Re-Start Oil Production Operations in Saskatchewan
Momentum Public Relations
Press Release: October 2, 2018
Hillcrest Petroleum Ltd. (the “Company”) ( TSX-V: HRH ) (OTCQB:HLRTF) is pleased to announce that it is commencing operations to re-start oil production from the West Hazel Oil field in Saskatchewan, with first oil sales expected in November, 2018.
Under the terms of its Joint Venture Agreement, the Company will provide 100% of reactivation costs to return the field to production through a wholly owned subsidiary to earn a 75% Working Interest, reverting to 50% after reactivation costs are paid back from cash flow .
The West Hazel field produced over 200 bbl/day oil before being shut in by the previous operator due to financial distress in 2015.
Restoring production from the West Hazel field includes refurbishing and upgrading production facilities including water disposal and returning four previously producing wells to production.
Initial oil production is expected to be between 150 and 250 bbl/day, with potential to increase to 500 bbl/day with further and previously unidentified well recompletions and development drilling in 2019.
Immediate reactivation costs are expected to total approximately $750,000.
For more information on Hillcrest Petroleum Ltd, contact Don Currie toll free at 1-855-609-0006 or visit the Company’s website at www.hillcrestpetroleum.com
ON BEHALF OF THE BOARD
Donald Currie
Chief Executive Officer and Director
- Published in Hillcrest Petroleum, Oil and Gas
Crop Announces Major Expansion in Italy
Momentum Public Relations
Press Release: October 1, 2018
CROP INFRASTRUCTRE CORP. (CSE: CROP) (OTC: CRXPF)(Frankfurt: 2FR) announced today that it has leased a 87,120 square foot greenhouse facility in Italy through its joint venture with XHemplar. Work has already begun on upgrading the site security which includes cameras and fencing.
In addition, CROP will be working with XHemplar to open two retail locations before the end of the year, as well as build a state-of-the-art extraction facility.
CROP Infrastructure CEO, Michael Yorke, stated: “This will allow for low-cost and high-quality pure CBD isolate and CBD products to be sold domestically as well as into the European CBD market. The joint venture’s CBD products will be branded under the XHemplar and CROP brands Tiffany CBD and Hempire Italia.
“This is a major increase in our European footprint. Not only will this expand our growing capacity and quality control, but, very importantly, the build-out of an extraction facility will allow CROP to provide European markets with quality CBD isolate.”
According to cannabis industry analysts the Brightfield Group, it is estimated the hemp-CBD market alone could hit $22 billion by 2022.
About CROP
Crop Infrastructure Corp. is publicly listed on the Canadian Securities Exchange and trades under the symbol “CROP” and in the US under the symbol “CRXPF”. CROP is primarily engaged in the business of investing, constructing, owning and leasing greenhouse projects as part of the provision of turnkey real estate solutions for lease-to-licensed cannabis producers and processors offering best-in-class operations. The Company’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada Cannabis farm, a 1,865 acre CBD farm, extraction in Nevada with international focuses in Jamaica and Italy and a joint venture on West Hollywood and San Bernardino dispensary applications.
CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage, US and Italian distribution rights to over 55 cannabis topical products and a portfolio of 16 Cannabis brands.
Company Contact
Michael Yorke – CEO & Director
E-mail: info@cropcorp.com
Website: www.cropcorp.com
Phone: (1) 604-484-4206
- Published in Business, CROP Infrastructure, Medical Marijuana, News Home